BEST UNLIMITED TURBO LONG CERTIFICATE - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:00 2024-05-17 pm EDT | ||
| 4.434 EUR | -7.12% |
|
| Current month | +2.61% | ||
| 1 month | +22.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 4.402 | -7.79% |
| 24-05-16 | 4.774 | -1.02% |
| 24-05-15 | 4.823 | +1.86% |
| 24-05-14 | 4.735 | +0.72% |
| 24-05-13 | 4.701 | +13.74% |
Real-time Euronext Paris
Last update May 17, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| FW98S | |
| ISIN | DE000SW7SJK8 |
| Date issued | 2024-03-15 |
| Strike | 739.2 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 5.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.286 € |
|---|---|
| Lowest since issue | 2.635 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Certificates
- FW98S Certificat
